Clinical Trial Update: An add-on Study to the FIGARO-DKD Study Called FIGARO-BM to Learn About the Link Between Biomarkers (Substances in the Blood Used as Indicators of Biological Processes, Disease Processes or Responses to Medication) and Finerenone in FIGARO-DKD Participants [Phase 2]

View source ↗

Summary

A Phase 2 add-on trial (FIGARO-BM) investigated the relationship between blood biomarkers and finerenone in participants from FIGARO-DKD (CKD with type 2 diabet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Type 2 Diabetes Mellitus

Drugs mentioned

• Finerenone (finerenone)

Snippet

Sponsor: Bayer | Conditions: Chronic Kidney Disease, Type 2 Diabetes Mellitus | Phase 2 | Status: COMPLETED | Results posted: 2023-03-31